Celgene Announces Positive Recommendation By Scottish Medicines Consortium (SMC) For ABRAXANE (Nab-Paclitaxel) In Combination With Gemcitabine1 For Patients With Metastatic Pancreatic Cancer

10 Feb 2015

·www.biospace.com

Antibody

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles; nab-paclitaxel), in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium (SMC) within the National Health Service Scotland.1 Help employers find you! Check out all the jobs and post your resume.

Organizations

Celgene Corp.Celgene International SARL

Indications

Pancreatic Cancer

Targets

Drugs

PaclitaxelGemcitabine

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.